In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of IBD
- Rapid Research and Development in Gastro Sciences
Challenges
- Stringent Product Approval Process
In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.3% |
|
Base Year Market Size (2024) |
USD 1.93 billion |
|
Forecast Year Market Size (2037) |
USD 3.78 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of in-vitro IBD diagnostic is assessed at USD 2.02 billion.
In-Vitro Inflammatory Bowel Disease (IBD) Diagnostic Market size was over USD 1.93 billion in 2024 and is projected to reach USD 3.78 billion by 2037, growing at around 5.3% CAGR during the forecast period i.e., between 2025-2037.
North America industry is estimated to account for largest revenue share of 44% by 2037, North America industry is estimated to account for largest revenue share of 44% by 2037
The major players in the market are are DiaSorin S.p.A., American Laboratory Products Company, Ltd. (d/b/a ALPCO Diagnostics), Quidel Corporation, CerTest Biotec, S.L., BUHLMANN Laboratories AG, and others.
